Lobbying client

FIDIA PHARMA USA

U.S. subsidiary of a global pharmaceutical leader in hyaluronic acid (HA) based products.

Filings
17
Filed by
1
Reported in-house
—
Reported by firms
$10,000

Reported lobbying by year

The larger of in-house and firm-reported each year, $ thousands 2017 to 2020

Filings

5 filings for 2017, newest first.
Filing Filed by Amount
4th Quarter - Report (No Activity)
4th Quarter 2017
MORGAN, LEWIS & BOCKIUS, LLP — reported
3rd Quarter - Report (No Activity)
3rd Quarter 2017
MORGAN, LEWIS & BOCKIUS, LLP — reported
2nd Quarter - Report (No Activity)
2nd Quarter 2017
MORGAN, LEWIS & BOCKIUS, LLP — reported
1st Quarter - Report
1st Quarter 2017
MORGAN, LEWIS & BOCKIUS, LLP $10,000 reported
Registration
1st Quarter 2017
MORGAN, LEWIS & BOCKIUS, LLP — reported

Filed by

Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.

FirmReportsAmount
MORGAN, LEWIS & BOCKIUS, LLP 16 $10,000

Issues lobbied

How many report sections named each issue, counting the current version of each report.

IssueCodeMentions
Medicare/Medicaid MMM 2

From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.